KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Other Non-Current Liabilities: 2011-2025

Historic Other Non-Current Liabilities for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to $11.1 million.

  • Arbutus Biopharma's Other Non-Current Liabilities rose 33.17% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 33.17%. This contributed to the annual value of $10.2 million for FY2024, which is 34.54% up from last year.
  • Arbutus Biopharma's Other Non-Current Liabilities amounted to $11.1 million in Q3 2025, which was up 2.78% from $10.8 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Other Non-Current Liabilities peaked at $19.4 million during Q1 2021, and registered a low of $7.6 million during Q4 2023.
  • In the last 3 years, Arbutus Biopharma's Other Non-Current Liabilities had a median value of $8.8 million in 2023 and averaged $9.2 million.
  • As far as peak fluctuations go, Arbutus Biopharma's Other Non-Current Liabilities slumped by 39.22% in 2023, and later surged by 35.00% in 2025.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Other Non-Current Liabilities stood at $16.3 million in 2021, then slumped by 36.40% to $10.4 million in 2022, then fell by 26.68% to $7.6 million in 2023, then spiked by 34.54% to $10.2 million in 2024, then soared by 33.17% to $11.1 million in 2025.
  • Its Other Non-Current Liabilities stands at $11.1 million for Q3 2025, versus $10.8 million for Q2 2025 and $10.5 million for Q1 2025.